Key Facts
- CAS
- 2805997-46-8
- Molecular Weight (MW)
- ≈4232 g/mol
- Half-life
- ~6 days (once-weekly)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 2/17/2026
- Targets
- GLP1R, GCGR
Overview
—
Protocol
- Dosage Range
- Investigational - dosage under evaluation in clinical trials
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Investigational - not yet established
Science
Mechanism of Action
Dual agonism for metabolic control, weight loss, fibrosis reduction.
Targets
GLP1R, GCGR
Studies
- — Journal/year not available
Benefits
Weight lossImproved liver fibrosisGlycemic control
Potential Side Effects
- GI symptoms (dose-dependent)
References
References coming soon.
Suggest a reference